Choose an application

• Reference Manager
• EndNote
• RefWorks (Direct export to RefWorks)

Frontotemporal dementia (FTD) is a cruel disease, robbing patients of core human characteristics and wreaking havoc with relationships. Clinical and scientific interest in FTD and related disorders continues to grow rapidly, with major advances having occurred since this book's last publication. New clinical diagnostic criteria were published in 2011; new pathological discoveries have led to new diagnostic criteria; and major genetic discoveries have been made. This new edition covers these developments, providing the leading resource on FTD, PPA, PSP, CBD, FTD-ALS, and related disorders, now written by a more internationally representative group of authors than before. Providing an in-depth and expert synthesis of the status of our knowledge of FTD and related syndromes, the content includes chapters reviewing clinical, neuropsychiatric, neuropsychological, imaging, and other features of FTD and multidisciplinary approaches to patient management. Essential reading for specialist and generalist neurologists, psychiatrists, geriatricians, neuropsychologists, neuropathologists, and basic scientists in relevant fields.

Dementia. --- Frontotemporal dementia.

Choose an application

• Reference Manager
• EndNote
• RefWorks (Direct export to RefWorks)

The world has a rapidly ageing population. Neurodegenerative diseases (ND) are strongly linked with age, with older citizens more at risk. Therefore the prevalence of ND is increasing dramatically. The major problem with ND is its difficulty to be diagnosed early. The goal of biomarker characterization is to increase certainty that a person has or does not have underlying pathology. During last decades, many research projects where focused on research on biomarkers for ND and this research has blasted into hundreds of scientific articles. However, few studies assessed their use in real clinical practice conditions. This Frontiers Research Topic is focused in the use of biomarkers for neurodegenerative disorders in the clinical setting. Topics include the use of biomarkers in the differential diagnosis of ND, the use of biomarkers to assess the risk of conversion from preclinical conditions, the use of biomarkers to follow up of clinical conditions and studies comparing biomarkers. We challenge to publish studies not only for the more frequent and more studied ND (Alzheimer’s and Parkinson’s diseases), but also for other less known ND such as prion diseases, motor neurone diseases, Huntington’s disease, spinocerebellar ataxia or spinal muscular atrophy among others. Biomarkers are very different in nature - from neuroimaging techniques to molecular parameters to be determined in the biochemical laboratory-. We welcome manuscripts reporting all kind of biomarkers since we wish to join and show together studies from different domains and thus give a perspective throughout the whole spectrum of research on biomarkers for ND.

Neurology. --- Neurodegenerative Diseases --- neurodegenerative disease --- Parkinson's disease --- MTAi --- biomarker --- Huntington's disease --- CSF biomarkers --- Frontotemporal dementia (FTD)

Choose an application

• Reference Manager
• EndNote
• RefWorks (Direct export to RefWorks)

The world has a rapidly ageing population. Neurodegenerative diseases (ND) are strongly linked with age, with older citizens more at risk. Therefore the prevalence of ND is increasing dramatically. The major problem with ND is its difficulty to be diagnosed early. The goal of biomarker characterization is to increase certainty that a person has or does not have underlying pathology. During last decades, many research projects where focused on research on biomarkers for ND and this research has blasted into hundreds of scientific articles. However, few studies assessed their use in real clinical practice conditions. This Frontiers Research Topic is focused in the use of biomarkers for neurodegenerative disorders in the clinical setting. Topics include the use of biomarkers in the differential diagnosis of ND, the use of biomarkers to assess the risk of conversion from preclinical conditions, the use of biomarkers to follow up of clinical conditions and studies comparing biomarkers. We challenge to publish studies not only for the more frequent and more studied ND (Alzheimer’s and Parkinson’s diseases), but also for other less known ND such as prion diseases, motor neurone diseases, Huntington’s disease, spinocerebellar ataxia or spinal muscular atrophy among others. Biomarkers are very different in nature - from neuroimaging techniques to molecular parameters to be determined in the biochemical laboratory-. We welcome manuscripts reporting all kind of biomarkers since we wish to join and show together studies from different domains and thus give a perspective throughout the whole spectrum of research on biomarkers for ND.

Neurology. --- Neurology --- Medicine --- Health & Biological Sciences --- Neurodegenerative Diseases --- neurodegenerative disease --- Parkinson's disease --- MTAi --- biomarker --- Huntington's disease --- CSF biomarkers --- Frontotemporal dementia (FTD)

Choose an application

• Reference Manager
• EndNote
• RefWorks (Direct export to RefWorks)

Under the name of Frontotemporal Dementias (FTD) numerous hereditary and sporadic disorders are listed. FTD may take away speech and language, social skills and ethical judgement, wishes and will, empathy and emotions; it may also impair motor functions. FTD may affect men and women in midlife or during old age leading to the demolition of the uniqueness of the human mind. In the last decade of the 20th century and in the first two decades of the 21st century, progress in the understanding of clinical, neuropathological, biochemical, and genetic aspects of FTD has accelerated. The novel awareness about FTD has directed young generations of researchers toward the study of this complex group of disorders. This Volume has been formulated with the participation of some of the leading scientists who have contributed to the development of knowledge in the clinical and basic science arenas. It captures the current central elements that are relevant to an up-to-date understanding of causes and pathogenesis of multiple forms of FTD. The volume is an opus that represents a distillation of the work of many scientists and addresses the current directions in the study of one of the most complex groups of diseases. In view of its structure, the book could also be used as a textbook, that offers both a broad and deep analysis of major areas in FTD. This book, planned by the International Society for Frontotemporal Dementias, is distinctive as it opens a window to a wide landscape about the biology of FTD. Thus, the book represents a moment of reflection on the present state of our knowledge of FTD and a collective vision toward scientific progress. The authors of each chapter share their knowledge and vision aimed at reducing the suffering which is caused by FTD.

Neurosciences. --- Neurology . --- Human genetics. --- Neurology. --- Human Genetics. --- Genetics --- Heredity, Human --- Human biology --- Physical anthropology --- Medicine --- Nervous system --- Neuropsychiatry --- Neural sciences --- Neurological sciences --- Neuroscience --- Medical sciences --- Diseases --- Frontotemporal dementia. --- Dementia, Frontotemporal --- Disinhibition-Dementia-Parkinsonism-Amyotrophy complex --- FLDEM (Frontotemporal lobe dementia) --- Frontotemporal lobe dementia --- FTD (Frontotemporal dementia) --- Hereditary dysphasic disinhibition dementia --- Wilhelmsen-Lynch disease --- Presenile dementia --- Medical genetics. --- Neuroscience. --- Medical Genetics. --- Clinical genetics --- Heredity of disease --- Human genetics --- Pathology --- Genetic disorders --- Genetic aspects

Choose an application

• Reference Manager
• EndNote
• RefWorks (Direct export to RefWorks)

Primary progressive aphasia is a clinical syndrome that includes a group of neurodegenerative disorders characterized by progressive language impairment. Our knowledge about this disorder has evolved significantly in recent years. Notably, correlations between clinical findings and pathology have improved, and main clinical, neuroimaging, and genetic features have been described. Furthermore, primary progressive aphasia is a good model for the study of brain–behavior relationships, and has contributed to the knowledge of the neural basis of language functioning. However, there are many open questions remaining. For instance, classification into three variants (non-fluent, semantic, and logopenic) is under debate; further data about epidemiology and natural history of the diseases are needed; and, as in other neurodegenerative disorders, successful therapies are lacking. The Guest Editors expect that this book can be very useful for scholars.

primary progressive aphasia --- informativeness --- speech production --- assessment --- diagnosis --- cognitive approach --- dementia --- frontotemporal dementia --- Alzheimer’s disease --- neuropsychology --- span --- sentence repetition --- working memory --- phonological --- visuospatial --- natural history --- mortality --- survival --- memory clinic --- graphical markers --- graphical parameters --- writing pressure --- differential diagnosis --- longitudinal assessment --- cognitive changes --- behavioural and psychological symptoms of dementia --- level of functioning --- electroencephalography --- resting-state --- biomarkers machine learning --- K-Nearest Neighbors --- graph theory --- treatment --- speech and language therapy --- intervention --- cognitive rehabilitation --- bilingualism --- semantic dementia --- semantic variant primary progressive aphasia --- word finding --- language therapy --- behavioural therapy --- electroencephalography (EEG) --- network analysis --- progressive apraxia of speech --- n/a --- Alzheimer's disease